Lunai Bioworks' Breakthrough: Lunai Bioworks has received its first Letter of Intent to license a next-generation immune cell therapy that has shown complete regression of pancreatic tumors in preclinical models, with no recurrence observed.
Clinical Trial Plans: The company is proposing a Phase I clinical trial for its Dendritic Cell Combination Therapy, targeting several high-need solid tumors, following positive results in humanized mouse models.
Expert Validation: The late Dr. Anahid Jewett praised the therapy's results, noting an 80%-90% reduction in tumor size and volume, with remaining tissue primarily consisting of immune cells, highlighting its potential significance in cancer research.
Future Developments: Lunai is preparing for formal licensing negotiations and pre-IND activities in early 2026, while also expanding its clinical reach through collaborations with other investigators.
Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
